drugset / Trial / NCT05431543

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

NCT05431543

Phase 2 Completed 59 enrolled LENZ Therapeutics, Inc
RandomizedCrossoverTriple-blindTreatment

Summary

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.

Timeline

Start
2022-08-06
Primary completion
2022-12-14
Completion
2022-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Aceclidine Small molecule
Subject Brimonidine Small molecule

Indications